BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes
April 13, 2023 14:03 ET
|
BioAegis Therapeutics
Gelsolin decreased microparticle-driven inflammation and mitigated activation of the NLRP3 inflammasome in type 2 diabetes. Low levels of gelsolin identified in individuals with type 2 diabetes...
$2.7 Billion Worldwide Pet Diabetes Care Industry to 2027 - Players Include ACON Laboratories, Allison Medical, i-SENS and Trividia Health
December 15, 2022 04:50 ET
|
Research and Markets
Dublin, Dec. 15, 2022 (GLOBE NEWSWIRE) -- The "Pet Diabetes Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Yale School of Medicine to Present Data on Reversal of Fatty Liver and Plasma Triglycerides in NHPs
February 04, 2020 08:30 ET
|
Crown Bioscience
SAN DIEGO, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Crown Bioscience today announced the presentation of new NAFLD/NASH data with Yale School of Medicine. The presentation encompasses preclinical...
Crown Bioscience Inc. and Charles River Laboratories Enter Agreement to Expand Access to ZDSD Rat Model
March 12, 2019 08:30 ET
|
Crown Bioscience
SAN DIEGO, Calif. and WILMINGTON, Mass., March 12, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance...
Crown Bioscience Expands Cardiovascular & Metabolic Disease Research Capability
November 08, 2018 08:00 ET
|
Crown Bioscience
The Company Offers New Non-GLP Services & Translational Rodent Models at its expanded site in Louisiana SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug...
Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring
November 23, 2017 08:00 ET
|
Crown Bioscience
SANTA CLARA, Calif., Nov. 23, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development...
CrownBio’s Translatable FATZO Model Utilized in Eli Lilly’s Preclinical Type 2 Diabetes Research Programs
November 21, 2017 08:00 ET
|
Crown Bioscience
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development...
CrownBio Enhances Its European Capabilities with New Generation of Innovative Translational Models for Obesity and Diabetes
October 10, 2017 09:31 ET
|
Crown Bioscience
SANTA CLARA, Calif., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development...
Crown Bioscience Names Laurie Heilmann Chief Business Officer; Executive Leader Brings Expertise in Global Strategy and Commercial Leadership to the Role
September 27, 2017 08:00 ET
|
Crown Bioscience
SANTA CLARA, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development...